Plozasiran (1) – Redemplo®
Familial chylomicronemia syndrome (FCS)
Characteristics
| Start date | 15.08.2026 |
|---|---|
| Resolution | 04.02.2027 – active procedure |
| INN | Plozasiran |
| Brand name | Redemplo® |
| Pharm. company | Arrowhead Pharmaceuticals Ireland Limited |
| G-BA Procedure ID | D-1358 |
| Therapeutic area | Metabolic diseases Orphan |
| Reason for procedure | Initial assessment |
Associated procedures
| Plozasiran (1) | Redemplo® | Arrowhead Pharmaceuticals Ireland Limited | Familial chylomicronemia syndrome (FCS) | n.d. | active procedure Orphan |
<< List of all resolutions